HR+/HER2- Breast Cancer Market Set To Triple
The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.
You may also be interested in...
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Novartis' Phase III MONALEESA-2 trial shows that ribociclib plus letrozole has strong efficacy and an acceptable tolerability profile for first-line advanced HR+/HER2- breast cancer patients, but analysts say the results do not surpass those of Pfizer's first-to-market Ibrance plus letrozole in a similar setting.
EU Approval Recommendation Secures Ibrance Domination
The EMA’s CHMP has recommended Ibrance for HR+/HER2- breast cancer and Pfizer may be able to establish a dominant position in the EU even quicker than it did in the US.
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.